Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,144 | 28,692 | 50,899 | 39,510 | 48,799 |
| TOTAL | $20,292 | $34,645 | $54,564 | $42,966 | $53,174 |
| Non-Current Assets | |||||
| PPE Net | 81 | 102 | 1,102 | 1,331 | 1,599 |
| Other Non-Current Assets | 811 | 1,032 | 1,803 | 2,169 | 2,824 |
| TOTAL | $892 | $1,134 | $2,905 | $3,500 | $4,423 |
| Total Assets | $21,184 | $35,779 | $57,469 | $46,466 | $57,597 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,439 | 6,220 | 9,166 | 8,034 | 2,995 |
| Accrued Expenses | 5,800 | 5,745 | 10,172 | 10,512 | 7,504 |
| TOTAL | $8,996 | $13,200 | $21,041 | $20,500 | $12,334 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 8,788 | 18,428 | 24,857 | 2,465 | 3,019 |
| TOTAL | $8,788 | $18,428 | $24,857 | $2,465 | $3,019 |
| Total Liabilities | $17,784 | $31,628 | $45,898 | $22,965 | $15,353 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 27,997 | 27,997 | 27,984 | 16,253 | 15,022 |
| Common Shares | 3 | 3 | 3 | 2 | 2 |
| Retained earnings | -317,844 | -316,670 | -307,569 | -288,833 | -262,110 |
| TOTAL | $3,400 | $4,151 | $11,571 | $23,501 | $42,244 |
| Total Liabilities And Equity | $21,184 | $35,779 | $57,469 | $46,466 | $57,597 |